Literature DB >> 15064394

Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.

Esti Liani1, Allon Eyal, Eyal Avraham, Revital Shemer, Raymonde Szargel, Daniela Berg, Antje Bornemann, Olaf Riess, Christopher A Ross, Ruth Rott, Simone Engelender.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disease characterized by Lewy body formation and death of dopaminergic neurons. Mutations in alpha-synuclein and parkin cause familial forms of PD. Synphilin-1 was shown to interact with alpha-synuclein and to promote the formation of cytosolic inclusions. We now report that synphilin-1 interacts with the E3 ubiquitin-ligases SIAH-1 and SIAH-2. SIAH proteins ubiquitylate synphilin-1 both in vitro and in vivo, promoting its degradation by the ubiquitin-proteasome system. Inability of the proteasome to degrade synphilin-1/SIAH complex leads to a robust formation of ubiquitylated cytosolic inclusions. Ubiquitylation is required for inclusion formation, because a catalytically inactive mutant of SIAH-1, which still binds to synphilin-1, fails to promote inclusions. Like synphilin-1, alpha-synuclein associates with SIAH in intact cells, but the interaction with SIAH-2 was much stronger that with SIAH-1. In vitro experiments show that SIAH-2 monoubiquitylates alpha-synuclein. Further evidence that SIAH proteins may play a role in inclusion formation comes from the demonstration of SIAH immunoreactivity in Lewy bodies of PD patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064394      PMCID: PMC397412          DOI: 10.1073/pnas.0401081101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

Review 1.  Aggresomes, inclusion bodies and protein aggregation.

Authors:  R R Kopito
Journal:  Trends Cell Biol       Date:  2000-12       Impact factor: 20.808

2.  Proteasomal function is impaired in substantia nigra in Parkinson's disease.

Authors:  K S McNaught; P Jenner
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

3.  The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility.

Authors:  Yichin Liu; Lara Fallon; Hilal A Lashuel; Zhihua Liu; Peter T Lansbury
Journal:  Cell       Date:  2002-10-18       Impact factor: 41.582

4.  Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells.

Authors:  C O'Farrell; D D Murphy; L Petrucelli; A B Singleton; J Hussey; M Farrer; J Hardy; D W Dickson; M R Cookson
Journal:  Brain Res Mol Brain Res       Date:  2001-12-16

5.  Regulation of synaptophysin degradation by mammalian homologues of seven in absentia.

Authors:  Tiffany C Wheeler; Lih-Shen Chin; Yankun Li; Francine L Roudabush; Lian Li
Journal:  J Biol Chem       Date:  2002-01-10       Impact factor: 5.157

6.  Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival.

Authors:  Gwang Lee; Eunsung Junn; Mikiei Tanaka; Yong Man Kim; M Maral Mouradian
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

7.  Degradation of alpha-synuclein by proteasome.

Authors:  M C Bennett; J F Bishop; Y Leng; P B Chock; T N Chase; M M Mouradian
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

8.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.

Authors:  Masato Hasegawa; Hideo Fujiwara; Takashi Nonaka; Koichi Wakabayashi; Hitoshi Takahashi; Virginia M-Y Lee; John Q Trojanowski; David Mann; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2002-10-10       Impact factor: 5.157

9.  Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein.

Authors:  Cátia S Ribeiro; Katia Carneiro; Christopher A Ross; João R L Menezes; Simone Engelender
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

10.  Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay.

Authors:  Michael Neystat; Margarita Rzhetskaya; Nikolai Kholodilov; Robert E Burke
Journal:  Neurosci Lett       Date:  2002-06-07       Impact factor: 3.046

View more
  72 in total

Review 1.  Nitric oxide-GAPDH-Siah: a novel cell death cascade.

Authors:  Makoto R Hara; Solomon H Snyder
Journal:  Cell Mol Neurobiol       Date:  2006-04-22       Impact factor: 5.046

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

Review 3.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

4.  α-Synuclein fate is determined by USP9X-regulated monoubiquitination.

Authors:  Ruth Rott; Raymonde Szargel; Joseph Haskin; Rina Bandopadhyay; Andrew J Lees; Vered Shani; Simone Engelender
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

5.  Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease.

Authors:  T Franck; R Krueger; D Woitalla; T Müller; S Engelender; O Riess
Journal:  J Neural Transm (Vienna)       Date:  2006-06-06       Impact factor: 3.575

6.  NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1.

Authors:  Kunikazu Tanji; Tomoaki Tanaka; Fumiaki Mori; Katsumi Kito; Hitoshi Takahashi; Koichi Wakabayashi; Tetsu Kamitani
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 7.  The ubiquitin ligase Siah2 and the hypoxia response.

Authors:  Koh Nakayama; Jianfei Qi; Ze'ev Ronai
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

8.  Site-specific differences in proteasome-dependent degradation of monoubiquitinated α-synuclein.

Authors:  Tharindumala Abeywardana; Yu Hsuan Lin; Ruth Rott; Simone Engelender; Matthew R Pratt
Journal:  Chem Biol       Date:  2013-10-24

Review 9.  The molecular programme of tumour reversion: the steps beyond malignant transformation.

Authors:  Adam Telerman; Robert Amson
Journal:  Nat Rev Cancer       Date:  2009-01-30       Impact factor: 60.716

10.  Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases.

Authors:  Katrin Beyer; Montserrat Domingo-Sábat; José I Lao; Cristina Carrato; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2007-10-23       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.